| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A century between pandemics and poisonings
|
Seftel, Matthew D
|
|
|
|
4 |
p. e251
|
artikel
|
| 2 |
Addition of four doses of rituximab to standard induction chemotherapy in adult patients with precursor B-cell acute lymphoblastic leukaemia (UKALL14): a phase 3, multicentre, randomised controlled trial
|
Marks, David I
|
|
|
|
4 |
p. e262-e275
|
artikel
|
| 3 |
An oral fixed-dose combination of decitabine and cedazuridine in myelodysplastic syndromes: a multicentre, open-label, dose-escalation, phase 1 study
|
Savona, Michael R
|
|
2019
|
|
4 |
p. e194-e203
|
artikel
|
| 4 |
Anticoagulant therapy for symptomatic calf deep vein thrombosis
|
Sartori, Michelangelo
|
|
2017
|
|
4 |
p. e156-
1 p.
|
artikel
|
| 5 |
Anticoagulant therapy for symptomatic calf deep vein thrombosis – Authors' reply
|
Righini, Marc
|
|
2017
|
|
4 |
p. e156-
1 p.
|
artikel
|
| 6 |
Antithrombin deficiency in pregnancy—the unresolved issues
|
Kovac, Mirjana
|
|
|
|
4 |
p. e276-e278
|
artikel
|
| 7 |
Anti-thymocyte globulin dosing—per kg or per lymphocyte?
|
Storek, Jan
|
|
2017
|
|
4 |
p. e154-e155
nvt p.
|
artikel
|
| 8 |
Appropriate management of polycythaemia vera with cytoreductive drug therapy: European LeukemiaNet 2021 recommendations
|
Marchetti, Monia
|
|
|
|
4 |
p. e301-e311
|
artikel
|
| 9 |
Association between anti-thymocyte globulin exposure and survival outcomes in adult unrelated haemopoietic cell transplantation: a retrospective, pharmacodynamic cohort analysis
|
Admiraal, Rick
|
|
2017
|
|
4 |
p. e183-e191
nvt p.
|
artikel
|
| 10 |
Be compliant or compromise?
|
Cheong, May Anne
|
|
|
|
4 |
p. e249
|
artikel
|
| 11 |
Bittersweet progress for haemophilia A
|
The Lancet Haematology,
|
|
2018
|
|
4 |
p. e127
|
artikel
|
| 12 |
Blood deserts: a vision to tackle blood inaccessibility
|
The Lancet Haematology,
|
|
|
|
4 |
p. e241
|
artikel
|
| 13 |
Blood, glorious blood
|
Gourd, Katherine
|
|
2015
|
|
4 |
p. e139-
1 p.
|
artikel
|
| 14 |
Breaking ground in haemophilia B gene therapy: insights from the HOPE-B trial and beyond
|
Ozelo, Margareth C
|
|
|
|
4 |
p. e243-e244
|
artikel
|
| 15 |
Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study
|
Berthon, Céline
|
|
2016
|
|
4 |
p. e186-e195
nvt p.
|
artikel
|
| 16 |
Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study
|
Amorim, Sandy
|
|
2016
|
|
4 |
p. e196-e204
nvt p.
|
artikel
|
| 17 |
Building an understanding of transgender care
|
The Lancet Haematology,
|
|
|
|
4 |
p. e241
|
artikel
|
| 18 |
Caesarean delivery and risk of childhood leukaemia: a pooled analysis from the Childhood Leukemia International Consortium (CLIC)
|
Marcotte, Erin L
|
|
2016
|
|
4 |
p. e176-e185
nvt p.
|
artikel
|
| 19 |
Can apixaban prevent venous thromboembolism better than rivaroxaban?
|
Akbashev, Mikhail
|
|
2019
|
|
4 |
p. e180
|
artikel
|
| 20 |
Can apixaban prevent venous thromboembolism better than rivaroxaban?
|
Coleman, Craig I
|
|
2019
|
|
4 |
p. e179
|
artikel
|
| 21 |
Can apixaban prevent venous thromboembolism better than rivaroxaban? – Authors' reply
|
Dawwas, Ghadeer K
|
|
2019
|
|
4 |
p. e181-e182
|
artikel
|
| 22 |
Cardio-oncology for better lymphoma therapy outcomes
|
Jurczak, Wojciech
|
|
|
|
4 |
p. e273-e275
|
artikel
|
| 23 |
Cardiovascular adverse events in patients with non-Hodgkin lymphoma treated with first-line cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or CHOP with rituximab (R-CHOP): a systematic review and meta-analysis
|
Linschoten, Marijke
|
|
|
|
4 |
p. e295-e308
|
artikel
|
| 24 |
CAR T-cell therapy roll-out in low-income and middle-income countries
|
Burki, Talha K
|
|
|
|
4 |
p. e252-e253
|
artikel
|
| 25 |
Chemotherapy-free treatment in non-Hodgkin lymphoma: a steep learning curve
|
Reagan, Patrick M
|
|
2017
|
|
4 |
p. e152-e153
nvt p.
|
artikel
|
| 26 |
Clinical development of voxtalisib: a pan-PI3K/mTOR inhibitor
|
Munakata, Wataru
|
|
2018
|
|
4 |
p. e134-e135
|
artikel
|
| 27 |
Combination of romidepsin with cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated patients with peripheral T-cell lymphoma: a non-randomised, phase 1b/2 study
|
Dupuis, Jehan
|
|
2015
|
|
4 |
p. e160-e165
nvt p.
|
artikel
|
| 28 |
Conditioning intensity in HCT for AML: the jury is still out
|
Craddock, Charles
|
|
2018
|
|
4 |
p. e132-e133
|
artikel
|
| 29 |
Correction to Lancet Haematol 2015; 2: e160
|
|
|
2015
|
|
4 |
p. e138-
1 p.
|
artikel
|
| 30 |
Correction to Lancet Haematol 2020; 7: e112–21
|
|
|
|
|
4 |
p. e249
|
artikel
|
| 31 |
Correction to Lancet Haematol 2021: 8: e254–66
|
|
|
|
|
4 |
p. e249
|
artikel
|
| 32 |
Correction to Lancet Haematol 2020; 7: e196–208
|
|
|
|
|
4 |
p. e279
|
artikel
|
| 33 |
Correction to Lancet Haematol 2019; 6: e551–61
|
|
|
|
|
4 |
p. e279
|
artikel
|
| 34 |
Correction to Lancet Haematol 2024; 11: e114–26
|
|
|
|
|
4 |
p. e248
|
artikel
|
| 35 |
Correction to Lancet Haematol 2016; 3: e176, e180
|
|
|
2016
|
|
4 |
p. e162-
1 p.
|
artikel
|
| 36 |
COVID-19 in a patient with chronic lymphocytic leukaemia
|
Jin, Xiang-Hong
|
|
|
|
4 |
p. e351-e352
|
artikel
|
| 37 |
10-day vs 5-day decitabine: equivalence cannot be concluded
|
Huls, Gerwin
|
|
2019
|
|
4 |
p. e177
|
artikel
|
| 38 |
10-day vs 5-day decitabine: equivalence cannot be concluded – Authors' reply
|
Short, Nicholas J
|
|
2019
|
|
4 |
p. e178
|
artikel
|
| 39 |
Defining global thresholds for anaemia: a challenging mission
|
Daru, Jahnavi
|
|
|
|
4 |
p. e242-e243
|
artikel
|
| 40 |
Derivation and external validation of the PLASMIC score for rapid assessment of adults with thrombotic microangiopathies: a cohort study
|
Bendapudi, Pavan K
|
|
2017
|
|
4 |
p. e157-e164
nvt p.
|
artikel
|
| 41 |
Dexamethasone plus oseltamivir versus dexamethasone in treatment-naive primary immune thrombocytopenia: a multicentre, randomised, open-label, phase 2 trial
|
Sun, Lu
|
|
|
|
4 |
p. e289-e298
|
artikel
|
| 42 |
Dissecting idiopathic multicentric Castleman's disease
|
Dupin, Nicolas
|
|
2016
|
|
4 |
p. e153-e154
nvt p.
|
artikel
|
| 43 |
Dulanermin in indolent lymphomas: an ineffective approach
|
Arcaini, Luca
|
|
2015
|
|
4 |
p. e136-e137
nvt p.
|
artikel
|
| 44 |
Dulanermin with rituximab in patients with relapsed indolent B-cell lymphoma: an open-label phase 1b/2 randomised study
|
Cheah, Chan Yoon
|
|
2015
|
|
4 |
p. e166-e174
nvt p.
|
artikel
|
| 45 |
Effective oral hypomethylating drugs in intermediate-risk or high-risk myelodysplasia: a breakthrough?
|
de Witte, Theo
|
|
2019
|
|
4 |
p. e170-e171
|
artikel
|
| 46 |
Effect of increased dose of total body irradiation on graft failure associated with HLA-haploidentical transplantation in patients with severe haemoglobinopathies: a prospective clinical trial
|
Bolaños-Meade, Javier
|
|
2019
|
|
4 |
p. e183-e193
|
artikel
|
| 47 |
Effect of red blood cell variants on childhood malaria in Mali: a prospective cohort study
|
Lopera-Mesa, Tatiana M
|
|
2015
|
|
4 |
p. e140-e149
nvt p.
|
artikel
|
| 48 |
Enasidenib: a magic bullet for myelodysplastic syndromes?
|
Santini, Valeria
|
|
|
|
4 |
p. e275-e276
|
artikel
|
| 49 |
Enasidenib in patients with mutant IDH2 myelodysplastic syndromes: a phase 1 subgroup analysis of the multicentre, AG221-C-001 trial
|
Stein, Eytan M
|
|
|
|
4 |
p. e309-e319
|
artikel
|
| 50 |
Endemic or regionally limited bacterial and viral infections in haematopoietic stem-cell transplantation recipients: a Worldwide Network for Blood and Marrow Transplantation (WBMT) Review
|
Muhsen, Ibrahim N
|
|
|
|
4 |
p. e284-e294
|
artikel
|
| 51 |
Endemic or regionally limited parasitic and fungal infections in haematopoietic stem-cell transplantation recipients: a Worldwide Network for Blood and Marrow Transplantation (WBMT) Review
|
Muhsen, Ibrahim N
|
|
|
|
4 |
p. e295-e305
|
artikel
|
| 52 |
Entwined lives: the day-to-day of a leukaemia doctor
|
Lucas, Catherine
|
|
|
|
4 |
p. e283
|
artikel
|
| 53 |
Eprenetapopt combined with venetoclax and azacitidine in TP53-mutated acute myeloid leukaemia: a phase 1, dose-finding and expansion study
|
Garcia-Manero, Guillermo
|
|
|
|
4 |
p. e272-e283
|
artikel
|
| 54 |
Ethnicity shouldn't matter
|
Pickaert, Anne-Pierre
|
|
|
|
4 |
p. e249
|
artikel
|
| 55 |
Etranacogene dezaparvovec gene therapy for haemophilia B (HOPE-B): 24-month post-hoc efficacy and safety data from a single-arm, multicentre, phase 3 trial
|
Coppens, Michiel
|
|
|
|
4 |
p. e265-e275
|
artikel
|
| 56 |
Excellent outcomes for patients with B-cell precursor acute lymphoblastic leukaemia with late bone marrow relapses
|
Teachey, David T
|
|
2019
|
|
4 |
p. e172-e173
|
artikel
|
| 57 |
Ferric carboxymaltose infusion versus oral iron supplementation for preoperative iron deficiency anaemia in patients with colorectal cancer (FIT): a multicentre, open-label, randomised, controlled trial
|
Talboom, Kevin
|
|
|
|
4 |
p. e250-e260
|
artikel
|
| 58 |
Follicular lymphoma: life beyond the third line
|
Montoto, Silvia
|
|
|
|
4 |
p. e241-e242
|
artikel
|
| 59 |
Fully oral regimen with decitabine and cedazuridine plus venetoclax: a new step forward for older or unfit patients with acute myeloid leukaemia
|
Candoni, Anna
|
|
|
|
4 |
p. e245-e246
|
artikel
|
| 60 |
Global representation among journal editors in haematology: are we diverse, equitable, and inclusive?
|
Noyola-Pérez, Andrés
|
|
|
|
4 |
p. e246-e247
|
artikel
|
| 61 |
Grb2 inhibition: a new potential targeted therapy for myeloid malignancies?
|
Thomas, Xavier
|
|
2018
|
|
4 |
p. e128-e129
|
artikel
|
| 62 |
Haematology in times of planetary instability
|
The Lancet Haematology,
|
|
|
|
4 |
p. e237
|
artikel
|
| 63 |
Haemoglobin thresholds to define anaemia from age 6 months to 65 years: estimates from international data sources
|
Braat, Sabine
|
|
|
|
4 |
p. e253-e264
|
artikel
|
| 64 |
Haemophilia—unparalleled progress but inadequate access
|
The Lancet Haematology,
|
|
|
|
4 |
p. e235
|
artikel
|
| 65 |
High cutoff versus high-flux haemodialysis for myeloma cast nephropathy in patients receiving bortezomib-based chemotherapy (EuLITE): a phase 2 randomised controlled trial
|
Hutchison, Colin A
|
|
2019
|
|
4 |
p. e217-e228
|
artikel
|
| 66 |
Hope for BET inhibition in patients with leukaemia or lymphoma
|
Kharfan-Dabaja, Mohamed A
|
|
2016
|
|
4 |
p. e157-e158
nvt p.
|
artikel
|
| 67 |
Hydroxyurea and stroke prevention in sickle cell anaemia: the challenge of application in sub-Saharan Africa
|
Diop, Saliou
|
|
|
|
4 |
p. e237-e238
|
artikel
|
| 68 |
Hydroxyurea with dose escalation for primary stroke risk reduction in children with sickle cell anaemia in Tanzania (SPHERE): an open-label, phase 2 trial
|
Ambrose, Emmanuela E
|
|
|
|
4 |
p. e261-e271
|
artikel
|
| 69 |
Idiopathic multicentric Castleman's disease: a systematic literature review
|
Liu, Amy Y
|
|
2016
|
|
4 |
p. e163-e175
nvt p.
|
artikel
|
| 70 |
Improved outcomes for extranodal natural killer T-cell lymphoma
|
Haverkos, Bradley M
|
|
|
|
4 |
p. e272-e273
|
artikel
|
| 71 |
Improvements in haploidentical transplantation for sickle cell disease and β-thalassaemia
|
Tisdale, John
|
|
2019
|
|
4 |
p. e168-e169
|
artikel
|
| 72 |
Improving quality of blood transfusion practices in Nigeria
|
Gwarzo, Dalhat
|
|
|
|
4 |
p. e250-e252
|
artikel
|
| 73 |
Intensified treatment of patients with early stage, unfavourable Hodgkin lymphoma: long-term follow-up of a randomised, international phase 3 trial of the German Hodgkin Study Group (GHSG HD14)
|
Gillessen, Sarah
|
|
|
|
4 |
p. e278-e288
|
artikel
|
| 74 |
2 + 2 in the long term: informing a new standard of care in 2021 for early stage, unfavourable Hodgkin lymphoma
|
Doo, Nicole Wong
|
|
|
|
4 |
p. e243-e245
|
artikel
|
| 75 |
Intravenous iron: a framework for changing the management of iron deficiency
|
Auerbach, Michael
|
|
|
|
4 |
p. e342-e350
|
artikel
|
| 76 |
In-vivo T-cell depleted reduced-intensity conditioned allogeneic haematopoietic stem-cell transplantation for patients with acute lymphoblastic leukaemia in first remission: results from the prospective, single-arm evaluation of the UKALL14 trial
|
Marks, David I
|
|
|
|
4 |
p. e276-e288
|
artikel
|
| 77 |
Iron deficiency in women: clearing the rust of silence
|
Tang, Catherine
|
|
|
|
4 |
p. e247-e248
|
artikel
|
| 78 |
Iron therapy for preoperative anaemia
|
Hands, Katie
|
|
|
|
4 |
p. e236-e237
|
artikel
|
| 79 |
Isaac Odame: combating both disease and disparity
|
Cavanaugh, Ray
|
|
|
|
4 |
p. e282
|
artikel
|
| 80 |
Late toxicities in non-Hodgkin lymphoma: extended follow-up matters
|
Thanarajasingam, Gita
|
|
|
|
4 |
p. e242-e243
|
artikel
|
| 81 |
Liposomal Grb2 antisense oligodeoxynucleotide (BP1001) in patients with refractory or relapsed haematological malignancies: a single-centre, open-label, dose-escalation, phase 1/1b trial
|
Ohanian, Maro
|
|
2018
|
|
4 |
p. e136-e146
|
artikel
|
| 82 |
Long-term efficacy of reduced-intensity versus myeloablative conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: retrospective follow-up of an open-label, randomised phase 3 trial
|
Fasslrinner, Frederick
|
|
2018
|
|
4 |
p. e161-e169
|
artikel
|
| 83 |
Long-term treatment with interferon alfa for myeloproliferative neoplasms
|
Kiladjian, Jean-Jacques
|
|
2017
|
|
4 |
p. e150-e151
nvt p.
|
artikel
|
| 84 |
Looking long-term: an unmet need in immune thrombocytopenia
|
Neunert, Cindy
|
|
|
|
4 |
p. e245-e246
|
artikel
|
| 85 |
Lucio Luzzatto: tackling blood disorders on multiple continents
|
Cavanaugh, Ray
|
|
|
|
4 |
p. e250
|
artikel
|
| 86 |
Meeting an unmet need for peripheral T-cell lymphoma
|
Lim, Soon Thye
|
|
2015
|
|
4 |
p. e134-e135
nvt p.
|
artikel
|
| 87 |
Melflufen in multiple myeloma: the conclusion matters
|
Hadidi, Samer Al
|
|
|
|
4 |
p. e244
|
artikel
|
| 88 |
Melflufen in multiple myeloma: the conclusion matters – Authors' reply
|
Schjesvold, Fredrik H
|
|
|
|
4 |
p. e244-e245
|
artikel
|
| 89 |
Models of care for sickle cell disease in low-income and lower-middle-income countries: a scoping review
|
Drown, Laura
|
|
|
|
4 |
p. e299-e308
|
artikel
|
| 90 |
Model solutions for ethical allocation during cancer medicine shortages
|
Hantel, Andrew
|
|
|
|
4 |
p. e246-e248
|
artikel
|
| 91 |
Myeloma cast nephropathy: the dusk of high cutoff haemodialysis
|
Sallée, Marion
|
|
2019
|
|
4 |
p. e174-e176
|
artikel
|
| 92 |
Neutrophil-erythrocyte rosettes suggestive of Coombs-negative autoimmune haemolysis
|
Cogan, Jacob C
|
|
|
|
4 |
p. e312
|
artikel
|
| 93 |
Nothing about us should be without us
|
Piggin, Maria
|
|
|
|
4 |
p. e248
|
artikel
|
| 94 |
Novel strategies in the treatment of acute lymphoblastic leukaemia
|
Advani, Anjali S
|
|
|
|
4 |
p. e240-e241
|
artikel
|
| 95 |
Oral decitabine and cedazuridine plus venetoclax for older or unfit patients with acute myeloid leukaemia: a phase 2 study
|
Bazinet, Alexandre
|
|
|
|
4 |
p. e276-e286
|
artikel
|
| 96 |
Outcomes of patients with childhood B-cell precursor acute lymphoblastic leukaemia with late bone marrow relapses: long-term follow-up of the ALLR3 open-label randomised trial
|
Parker, Catriona
|
|
2019
|
|
4 |
p. e204-e216
|
artikel
|
| 97 |
Paediatric to adult transition care for patients with sickle cell disease: a global perspective
|
Inusa, Baba Psalm Duniya
|
|
|
|
4 |
p. e329-e341
|
artikel
|
| 98 |
Patients are also experts
|
Lewis, Chris
|
|
|
|
4 |
p. e280
|
artikel
|
| 99 |
Pegylated interferon alfa-2a in patients with essential thrombocythaemia or polycythaemia vera: a post-hoc, median 83 month follow-up of an open-label, phase 2 trial
|
Masarova, Lucia
|
|
2017
|
|
4 |
p. e165-e175
nvt p.
|
artikel
|
| 100 |
Phase 1 clinical trials and toxicity
|
The Lancet Haematology,
|
|
2017
|
|
4 |
p. e147-
1 p.
|
artikel
|
| 101 |
Pleural fluid overload-associated large B-cell lymphoma with a formerly double-hit genotype
|
Liaskas, Athanasios
|
|
|
|
4 |
p. e306
|
artikel
|
| 102 |
Prehospital blood transfusion: who benefits?
|
Thies, Karl-Christian
|
|
|
|
4 |
p. e238-e239
|
artikel
|
| 103 |
Quality of control groups in randomised trials of multiple myeloma enrolling in the USA: a systematic review
|
Mohyuddin, Ghulam Rehman
|
|
|
|
4 |
p. e299-e304
|
artikel
|
| 104 |
Reactivating hope for TP53-mutated acute myeloid leukaemia?
|
Bug, Gesine
|
|
|
|
4 |
p. e239-e240
|
artikel
|
| 105 |
Ready-to-use food supplement, with or without arginine and citrulline, with daily chloroquine in Tanzanian children with sickle-cell disease: a double-blind, random order crossover trial
|
Cox, Sharon E
|
|
2018
|
|
4 |
p. e147-e160
|
artikel
|
| 106 |
Real life studies and good clinical practice
|
Stephan, Dominique
|
|
2016
|
|
4 |
p. e160-
1 p.
|
artikel
|
| 107 |
Real life studies and good clinical practice – Authors' reply
|
Ageno, Walter
|
|
2016
|
|
4 |
p. e160-e161
nvt p.
|
artikel
|
| 108 |
Red blood cell variants and malaria: a long story not yet over
|
Williams, Thomas Neil
|
|
2015
|
|
4 |
p. e130-e131
nvt p.
|
artikel
|
| 109 |
Reduced dose azacitidine plus venetoclax as maintenance therapy in acute myeloid leukaemia following intensive or low-intensity induction: a single-centre, single-arm, phase 2 trial
|
Bazinet, Alexandre
|
|
|
|
4 |
p. e287-e298
|
artikel
|
| 110 |
Resuscitation with blood products in patients with trauma-related haemorrhagic shock receiving prehospital care (RePHILL): a multicentre, open-label, randomised, controlled, phase 3 trial
|
Crombie, Nicholas
|
|
|
|
4 |
p. e250-e261
|
artikel
|
| 111 |
Risk of bleeding and arterial thromboembolism in patients with non-valvular atrial fibrillation either maintained on a vitamin K antagonist or switched to a non-vitamin K-antagonist oral anticoagulant: a retrospective, matched-cohort study
|
Bouillon, Kim
|
|
2015
|
|
4 |
p. e150-e159
nvt p.
|
artikel
|
| 112 |
Risk of pregnancy-related venous thromboembolism and obstetrical complications in women with inherited type I antithrombin deficiency: a retrospective, single-centre, cohort study
|
Abbattista, Maria
|
|
|
|
4 |
p. e320-e328
|
artikel
|
| 113 |
Rituximab plus high-dose chemotherapy (MegaCHOEP) or conventional chemotherapy (CHOEP-14) in young, high-risk patients with aggressive B-cell lymphoma: 10-year follow-up of a randomised, open-label, phase 3 trial
|
Frontzek, Fabian
|
|
|
|
4 |
p. e267-e277
|
artikel
|
| 114 |
Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials
|
Smith, Sonali M
|
|
2017
|
|
4 |
p. e176-e182
nvt p.
|
artikel
|
| 115 |
Sex and gender reporting advances in medicine
|
The Lancet Haematology,
|
|
|
|
4 |
p. e241
|
artikel
|
| 116 |
Sex specific definitions of anaemia reflect androgen production
|
Spivak, Jerry L
|
|
|
|
4 |
p. e243
|
artikel
|
| 117 |
Sex specific definitions of anaemia reflect androgen production – Authors' reply
|
Weyand, Angela C
|
|
|
|
4 |
p. e243-e244
|
artikel
|
| 118 |
Shaking up the system
|
The Lancet Haematology,
|
|
2015
|
|
4 |
p. e129-
1 p.
|
artikel
|
| 119 |
Sickle-cell anaemia—keeping alive Wethers' legacy
|
The Lancet Haematology,
|
|
2019
|
|
4 |
p. e167
|
artikel
|
| 120 |
Sickle-cell anaemia needs more food?
|
Hyacinth, Hyacinth I
|
|
2018
|
|
4 |
p. e130-e131
|
artikel
|
| 121 |
Stressful exit from the womb and risk of childhood leukaemia
|
Wiemels, Joseph
|
|
2016
|
|
4 |
p. e155-e156
nvt p.
|
artikel
|
| 122 |
Survival outcomes of patients with extranodal natural-killer T-cell lymphoma: a prospective cohort study from the international T-cell Project
|
Fox, Christopher P
|
|
|
|
4 |
p. e284-e294
|
artikel
|
| 123 |
Switching from a vitamin K antagonist to a NOAC
|
Senoo, Keitaro
|
|
2015
|
|
4 |
p. e132-e133
nvt p.
|
artikel
|
| 124 |
Technological advances or Emperor's new clothes?
|
The Lancet Haematology,
|
|
2016
|
|
4 |
p. e149-
1 p.
|
artikel
|
| 125 |
Thank you to our 2022 peer reviewers and an update on inclusion and diversity
|
The Lancet Haematology,
|
|
|
|
4 |
p. e241
|
artikel
|
| 126 |
Thank you to The Lancet Haematology's peer reviewers in 2022
|
The Lancet Haematology,
|
|
|
|
4 |
p. e242-e245
|
artikel
|
| 127 |
The collaborative network approach: a new framework to accelerate Castleman's disease and other rare disease research
|
Fajgenbaum, David C
|
|
2016
|
|
4 |
p. e150-e152
nvt p.
|
artikel
|
| 128 |
The evolving role of stem cell transplantation
|
The Lancet Haematology,
|
|
|
|
4 |
p. e271
|
artikel
|
| 129 |
The 2015 Focus on Haematology winner
|
The Lancet Haematology,
|
|
2016
|
|
4 |
p. e159-
1 p.
|
artikel
|
| 130 |
The PLASMIC score for thrombotic thrombocytopenic purpura
|
Jamme, Matthieu
|
|
2017
|
|
4 |
p. e148-e149
nvt p.
|
artikel
|
| 131 |
The rollercoaster of vaccine-induced immune thrombotic thrombocytopenia
|
Cliff, Edward R Scheffer
|
|
|
|
4 |
p. e246
|
artikel
|
| 132 |
The Sickle Cell Guide—equity for patients
|
Parris, Elliott
|
|
|
|
4 |
p. e249
|
artikel
|
| 133 |
Time to define and refine maintenance strategies in acute myeloid leukaemia
|
Chua, Chong Chyn
|
|
|
|
4 |
p. e246-e247
|
artikel
|
| 134 |
Treatment patterns and outcomes of patients with relapsed or refractory follicular lymphoma receiving three or more lines of systemic therapy (LEO CReWE): a multicentre cohort study
|
Casulo, Carla
|
|
|
|
4 |
p. e289-e300
|
artikel
|
| 135 |
Ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukaemia (GENUINE): a phase 3, multicentre, open-label, randomised trial
|
Sharman, Jeff P
|
|
|
|
4 |
p. e254-e266
|
artikel
|
| 136 |
Voxtalisib (XL765) in patients with relapsed or refractory non-Hodgkin lymphoma or chronic lymphocytic leukaemia: an open-label, phase 2 trial
|
Brown, Jennifer R
|
|
2018
|
|
4 |
p. e170-e180
|
artikel
|
| 137 |
What problems do you face that digital health could solve?
|
McCafferty, Conor
|
|
|
|
4 |
p. e281
|
artikel
|
Tijdschrift beschrijving